DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 110.2% during the fourth quarter, HoldingsChannel reports. The firm owned 20,345 shares of the medical device company’s stock after buying an additional 10,666 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in DexCom were worth $1,582,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of DXCM. Watts Gwilliam & Co. LLC acquired a new stake in DexCom during the 4th quarter valued at $3,334,000. Congress Asset Management Co. grew its stake in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock worth $18,085,000 after acquiring an additional 222,548 shares during the last quarter. First Hawaiian Bank lifted its stake in shares of DexCom by 556.1% in the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company’s stock worth $1,801,000 after acquiring an additional 19,629 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in DexCom in the fourth quarter valued at about $5,812,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 2.3 %

DXCM opened at $85.29 on Friday. The stock’s fifty day moving average is $71.03 and its 200-day moving average is $77.09. DexCom, Inc. has a one year low of $57.52 and a one year high of $132.26. The company has a market capitalization of $33.44 billion, a PE ratio of 59.64, a P/E/G ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.32 EPS. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Robert W. Baird cut their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Barclays boosted their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a research report on Monday. Canaccord Genuity Group lifted their price target on DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Cfra Research upgraded DexCom to a “hold” rating in a research note on Friday, March 21st. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $98.11.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock worth $4,734,384 in the last three months. 0.32% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.